Publication | Closed Access

Ibritumomab tiuxetan (Zevalin) combined with reduced-intensity conditioning and allogeneic stem-cell transplantation (SCT) in patients with chemorefractory non-Hodgkin's lymphoma

Lymphoid NeoplasiaRadiation OncologyIbritumomab TiuxetanTransplantationReduced-intensity ConditioningCell TherapyMedicineImmunologyPathologyAllogeneic Stem-cell TransplantationImmunotherapyOncologyCell Transplantation